TY - JOUR
T1 - Incidence of Lymphomas and Other Cancers in HIV-Infected and HIV-Uninfected Patients With Hemophilia
AU - Rabkin, Charles S.
AU - Hilgartner, Margaret W.
AU - Hedberg, Katie W.
AU - Aledort, Louis M.
AU - Hatzakis, Angelos
AU - Eichinger, Sabine
AU - Eyster, M. Elaine
AU - White, Gilbert C.
AU - Kessler, Craig M.
AU - Lederman, Michael M.
AU - Moerloose, Philippe
AU - Bray, Gordon L.
AU - Cohen, Alan R.
AU - Andes, W. Abe
AU - Manco Johnson, Marilyn
AU - Schramm, Wolfgang
AU - Kroner, Barbara L.
AU - Blattner, William A.
AU - Goedert, James J.
PY - 1992/2/26
Y1 - 1992/2/26
N2 - Objective.—To determine the types and rates of cancers occurring in excess in the presence of infection with the human immunodeficiency virus type 1 (HIV-1). Design.—Cohort analytic study of HIV-infected and HIV-uninfected subjects followed for up to 12 years. Setting.—Fifteen hemophilia treatment centers. Patients.—A total of 1701 patients with hemophilia, of whom 1065 (63%) were HIV-1 seropositive. Main Outcome Measures.—Morphologic classification and incidence rates of cancers. Main Results.—The incidence of non-Hodgkin’s lymphoma after HIV seroconversion averaged 0.15 case per 100 person-years (95% confidence interval [CI], 0.08 to 0.25) and rose exponentially with increasing duration of HIV infection. Although the greatest absolute risk of lymphoma was in the oldest age group, the relative increase compared with general population rates was 38-fold in subjects 10 to 39 years old and 12-fold in older subjects (P<.05). The CD4+ T-lymphocyte levels for lymphoma cases were similar to HIV-positive subjects without the acquired immunodeficiency syndrome (AIDS) who had been infected for the same length of time. The incidence of Kaposi’s sarcoma was increased 200-fold (95% CI, 20 to 700). The incidence of cancers other than non-Hodgkin’s lymphoma and Kaposi’s sarcoma were not increased in the HIV-positive subjects (ratio of observed to expected cases, 0.9 [95% CI, 0.4 to 1.9]). The HIV-negative subjects had no significant increase in cancer incidence. Conclusions.—HIV infection has restricted effects on cancer incidence that are only partly explained by immunosuppression. Paradoxically, improvements in therapy of HIV infection that prolong survival may lead to further increases in HIVassociated lymphoma.
AB - Objective.—To determine the types and rates of cancers occurring in excess in the presence of infection with the human immunodeficiency virus type 1 (HIV-1). Design.—Cohort analytic study of HIV-infected and HIV-uninfected subjects followed for up to 12 years. Setting.—Fifteen hemophilia treatment centers. Patients.—A total of 1701 patients with hemophilia, of whom 1065 (63%) were HIV-1 seropositive. Main Outcome Measures.—Morphologic classification and incidence rates of cancers. Main Results.—The incidence of non-Hodgkin’s lymphoma after HIV seroconversion averaged 0.15 case per 100 person-years (95% confidence interval [CI], 0.08 to 0.25) and rose exponentially with increasing duration of HIV infection. Although the greatest absolute risk of lymphoma was in the oldest age group, the relative increase compared with general population rates was 38-fold in subjects 10 to 39 years old and 12-fold in older subjects (P<.05). The CD4+ T-lymphocyte levels for lymphoma cases were similar to HIV-positive subjects without the acquired immunodeficiency syndrome (AIDS) who had been infected for the same length of time. The incidence of Kaposi’s sarcoma was increased 200-fold (95% CI, 20 to 700). The incidence of cancers other than non-Hodgkin’s lymphoma and Kaposi’s sarcoma were not increased in the HIV-positive subjects (ratio of observed to expected cases, 0.9 [95% CI, 0.4 to 1.9]). The HIV-negative subjects had no significant increase in cancer incidence. Conclusions.—HIV infection has restricted effects on cancer incidence that are only partly explained by immunosuppression. Paradoxically, improvements in therapy of HIV infection that prolong survival may lead to further increases in HIVassociated lymphoma.
UR - http://www.scopus.com/inward/record.url?scp=0026592656&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0026592656&partnerID=8YFLogxK
U2 - 10.1001/jama.1992.03480080060027
DO - 10.1001/jama.1992.03480080060027
M3 - Article
C2 - 1735926
AN - SCOPUS:0026592656
SN - 0098-7484
VL - 267
SP - 1090
EP - 1094
JO - JAMA: The Journal of the American Medical Association
JF - JAMA: The Journal of the American Medical Association
IS - 8
ER -